Medication discovery for addiction: Translating the dopamine D3 receptor hypothesis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The dopamine D3 receptor (D3R) has been investigated as a potential target for medication development to treat substance use disorders (SUDs) with a particular focus on cocaine and methamphetamine. Currently, there are no approved medications to treat cocaine and methamphetamine addiction and thus developing pharmacotherapeutics to compliment existing behavioral strategies is a fundamental goal. Novel compounds with high affinity and D3R selectivity have been evaluated in numerous animal models of drug abuse and favorable outcomes in nonhuman primate models of self-administration and relapse have provided compelling evidence to advance these agents into the clinic. One approach is to repurpose drugs that share the D3R mechanism and already have clinical utility, and to this end buspirone has been identified as a viable candidate for clinical trials. A second, but substantially more resource intensive and risky approach involves the development of compounds that exclusively target D3R, such as GSK598809 and PG 619. Clinical investigation of these drugs or other novel D3R-selective agents will provide a better understanding of the role D3R plays in addiction and whether or not antagonists or partial agonists that are D3R selective are effective in achieving abstinence in this patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dopamine receptors: from structure to function
MISSALE, C., NASH, S. R., ROBINSON, S. W., JABER, M., & CARON, M. G. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.1.189 · Cited by 3,633
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“Further, the multi-billion dollar price tag [3] coupled with the high risk of developing”
BackgroundKoob, G. F., Sanna, P. P., & Bloom, F. E. (1998) · Neuron · doi:10.1016/s0896-6273(00)80557-7 · Cited by 1,026
Volkow, N. D., Fowler, J. S., Wang, G., Hitzemann, R., Logan, J., Schlyer, D. J., Dewey, S. L., & Wolf, A. P. (1993) · Synapse · doi:10.1002/syn.890140210 · Cited by 924
PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys
Nader, M. A., Morgan, D., Gage, H. D., Nader, S. H., Calhoun, T. L., Buchheimer, N., Ehrenkaufer, R., & Mach, R. H. (2006) · Nature Neuroscience · doi:10.1038/nn1737 · Cited by 481
Self-citationBeardsley, P. M., Shelton, K. L., Hendrick, E., & Johnson, K. W. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.04.010 · Cited by 97
Cited by
Moore, T. J., Glenmullen, J., & Mattison, D. R. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.5262 · Cited by 324
Substance use disorders: Psychoneuroimmunological mechanisms and new targets for therapy
Loftis, J. M., & Huckans, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.04.011 · Cited by 47
Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction
Cao, D.-N., Shi, J.-J., Hao, W., Wu, N., & Li, J. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.03.040 · Cited by 34
Metadata
- Authors
- Newman, A. H., Blaylock, B. L., Nader, M. A., Bergman, J., Sibley, D. R., & Skolnick, P.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 84
- Issue
- 7
- Pages
- 882-890
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2090518397
- Cited by
- 134
- References
- 6
- FWCI
- 7.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medication discovery for addiction: Translating the dopamine D3 receptor hypothesis. https://app.cochat.ai/papers/10.1016/j.bcp.2012.06.023
- The paper
- Newman, A. H., Blaylock, B. L., Nader, M. A., Bergman, J., Sibley, D. R., & Skolnick, P. (2012). Medication discovery for addiction: Translating the dopamine D3 receptor hypothesis. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2012.06.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.